

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

TATA Health International Holdings Limited

TATA 健康國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1255)

(1) DELAY IN PUBLICATION OF 2023 ANNUAL RESULTS AND DESPATCH OF 2023 ANNUAL REPORT; (2) POSTPONEMENT OF THE BOARD MEETING; AND (3) EXPECTED DATE TO PUBLISH THE 2023 ANNUAL RESULTS

Reference is made to the announcements made by the board (the “**Board**”) of directors (the “**Directors**”) of TATA Health International Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 1 August 2018, 25 March 2024, 2 April 2024, 12 April 2024, 18 April 2024 (collectively the “**Announcements**”) pursuant to, among other things, Rules 13.09(2)(a), 13.46(2) and 13.49(1) of the Rules (the “**Listing Rules**”) governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”). Unless otherwise defined, capitalised terms used in this announcement have the same meanings as those defined in the Announcements.

DELAY IN PUBLICATION OF ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023 AND DESPATCH OF THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

The Board wishes to inform the Shareholders that there will be a further delay in publication of the 2023 Annual Results because, as at the date of this announcement, the Company is still in the process of collecting and collating the necessary information and documents from its subsidiaries as required by the Auditor to complete the auditing process. The outstanding documents and/or procedures are as follows:

- (a) To obtain books and records of the Company’s certain subsidiaries and associates in the PRC and Australia;
- (b) To evaluate the expected credit loss assessment on the Loan to Century Health Holdings Co., Ltd. (“**Century Health**”) pursuant to the Loan Agreement (including and not limited to obtaining legal opinion, valuation reports from management experts including loan and relevant supporting documents);

- (c) To complete the valuation report in relation to the impairment assessment on (i) the non-current assets of the Company's subsidiaries in Hong Kong and (ii) properties' valuation; and
- (d) To project the Group's working capital forecast for the next 12 months and to obtain the relevant supporting documents.

The Company is still in the process of communicating closely with its subsidiaries and the Auditor to gather all requisite information and documents to complete the audit procedures.

Pursuant to Rule 13.49(1) of the Listing Rules, the Company is required to publish the 2023 Annual Results no later than three months after the end of the financial year (i.e. on or before 31 March 2024). Delay in publishing the 2023 Annual Results constitutes non-compliance with Rule 13.49(1) of the Listing Rules.

Pursuant to Rule 13.49(3) of the Listing Rules, if the Company is unable to publish the 2023 Annual Results within the prescribed timeframe, it must announce its results prepared based on the financial results which have yet been agreed upon with the auditors (so far as such information is available). The Board, after due and careful consideration, is of the view that it would not be appropriate for the Company to publish the unaudited management accounts of the Group for the year ended 31 December 2023 at this stage as they may not accurately reflect the financial performance and/or position of the Group and the publication of the unaudited management accounts could cause confusion and may be misleading to the Shareholders and potential investors of the Company.

Pursuant to Rule 13.46(2) of the Listing Rules, the Company is required to despatch the 2023 Annual Report to the Shareholders no later than four months after the end of the financial year (i.e. on or before 30 April 2024). Due to the delay in the publication of the 2023 Annual Results, it is expected that there may be a possible delay in the despatch of the 2023 Annual Report. Based on current progress, the expected date of the publication of the 2023 Annual Results will be by the end of July 2024.

POSTPONEMENT OF THE BOARD MEETING

In light of the delay in publication of the 2023 Annual Results, the meeting of the Board for approving the 2023 Annual Results (the "**Board Meeting**") will also be further delayed. Further announcement(s) will be made by the Company in accordance with the Listing Rules and the requirement under the SFO as and when it is appropriate.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on 2 April 2024, and will remain suspended pending the release of an announcement for the 2023 Annual Results. The Company will keep the public informed of the latest developments by making further announcement(s) as and when appropriate.

The Shareholders and potential investors of the Company are advised to invest cautiously and to be aware of the investment risks.

By Order of the Board
TATA Health International Holdings Limited

Hong Kong, 5 June 2024

As at the date of this announcement, the Board comprises three non-executive Directors, namely, Mr. Lin Zheming, Mr. Chu Chun Ho, Dominic and Ms. Jiang Juqi; and three independent non-executive Directors, namely, Mr. Wang Jian, Mr. Tao Chi Keung and Mr. Cai Tsz Yeung.